Literature DB >> 16641464

Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats.

Seulki Lee1, Sang Kyoon Kim, Dong Yun Lee, Su Young Chae, Youngro Byun.   

Abstract

Oral administration of ceftriaxone associated with a bile acid-based new oral carrier, cholylethylenediamine, in 50% propylene glycol to rats at doses of 25 and 50 mg/kg of body weight resulted in a significant increase in intestinal absorption, as evidenced by 55% improvement in the bioavailability, whereas ceftriaxone alone showed a bioavailability of less than 1%.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641464      PMCID: PMC1472223          DOI: 10.1128/AAC.50.5.1869-1871.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Solubilizing excipients in oral and injectable formulations.

Authors:  Robert G Strickley
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

2.  Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B.

Authors:  R L de Vrueh; E T Rump; E van De Bilt; R van Veghel; J Balzarini; E A Biessen; T J van Berkel; M K Bijsterbosch
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 3.  Pathophysiology of the enterohepatic circulation of bile acids.

Authors:  S Matern; W Gerok
Journal:  Rev Physiol Biochem Pharmacol       Date:  1979       Impact factor: 5.545

4.  Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers.

Authors:  B R Meyers; E S Srulevitch; J Jacobson; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

5.  A new drug carrier, Nalpha-deoxycholyl-L: -lysyl-methylester, for enhancing insulin absorption in the intestine.

Authors:  S Lee; J Lee; D Y Lee; S K Kim; Y Lee; Y Byun
Journal:  Diabetologia       Date:  2005-03-01       Impact factor: 10.122

6.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

Review 7.  Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life.

Authors:  T R Beam
Journal:  Pharmacotherapy       Date:  1985 Sep-Oct       Impact factor: 4.705

8.  Enhanced oral bioavailability of poorly absorbed drugs. I. Screening of absorption carrier for the ceftriaxone complex.

Authors:  Seong-Wan Cho; Jeoung Soo Lee; Seung-Ho Choi
Journal:  J Pharm Sci       Date:  2004-03       Impact factor: 3.534

Review 9.  Polymeric materials containing bile acids.

Authors:  Xiao-Xia Zhu; Marieta Nichifor
Journal:  Acc Chem Res       Date:  2002-07       Impact factor: 22.384

Review 10.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more
  7 in total

Review 1.  Bile acid transporter-mediated oral drug delivery.

Authors:  Feiyang Deng; You Han Bae
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

2.  Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates.

Authors:  Ok-Cheol Jeon; Seung Rim Hwang; Taslim A Al-Hilal; Jin Woo Park; Hyun Tae Moon; Seulki Lee; Jae Hyung Park; Youngro Byun
Journal:  Pharm Res       Date:  2013-01-05       Impact factor: 4.200

3.  Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium.

Authors:  Noha M Zaki; Mohamed M Hafez
Journal:  AAPS PharmSciTech       Date:  2012-02-23       Impact factor: 3.246

4.  Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria.

Authors:  Phuoc Vinh Nguyen; Clémentine Aubry; Narimane Boudaoud; Alexandra Gaubert; Marie-Hélène Langlois; Mathieu Marchivie; Karen Gaudin; Corinne Arpin; Philippe Barthélémy; Tina Kauss
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

5.  Time to abandon ampicillin plus gentamicin in favour of ampicillin plus ceftriaxone in Enterococcus faecalis infective endocarditis? A meta-analysis of comparative trials.

Authors:  Moritz Mirna; Albert Topf; Lukas Schmutzler; Uta C Hoppe; Michael Lichtenauer
Journal:  Clin Res Cardiol       Date:  2021-11-09       Impact factor: 6.138

6.  Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions.

Authors:  Boubakar Ba; Karen Gaudin; Amélie Désiré; Thida Phoeung; Marie-Hélène Langlois; Charan R Behl; Joel Unowsky; Indravadan H Patel; A Waseem Malick; Melba Gomes; Nicholas White; Tina Kauss
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

7.  Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children.

Authors:  Shashikant Srivastava; Johanna van Zyl; Kayle Cirrincione; Katherine Martin; Tania Thomas; Devyani Deshpande; Jan-William Alffenaar; James A Seddon; Tawanda Gumbo
Journal:  Pediatr Infect Dis J       Date:  2020-12       Impact factor: 3.806

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.